Enliven Therapeutics earnings were -$100.2M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest ELVN earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$25.3M, down 11.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ELVN reported annual earnings of -$89.0M, with 24.4% growth. The next ELVN earnings date is Nov 6, 2025.
Enliven Therapeutics Earnings Reports & History FAQ
What were Enliven Therapeutics's earnings last quarter?
On ELVN's earnings call on Invalid Date, Enliven Therapeutics (NASDAQ: ELVN) reported Q2 2025 earnings per share (EPS) of -$0.49, up 19.51% year over year. Total ELVN earnings for the quarter were -$25.34 million. In the same quarter last year, Enliven Therapeutics's earnings per share (EPS) was -$0.41.
The next ELVN earnings call is Invalid Date. Add ELVN to your watchlist to be reminded of Enliven Therapeutics's next earnings date.
Is Enliven Therapeutics profitable or losing money?
As of the last Enliven Therapeutics earnings report, Enliven Therapeutics is currently losing money. Enliven Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$100.22 million, a 20.99% increase year over year.
What was ELVN's earnings growth in the past year?
As of Enliven Therapeutics's earnings date in Invalid Date, Enliven Therapeutics's earnings has grown year over year. ELVN earnings in the past year totalled -$100.22 million.
What are Enliven Therapeutics's earnings expectations?
The current EPS estimate for Enliven Therapeutics's earnings report in Invalid Date is -$0.50.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.